This is the first time that Splink has received this award as a medical AI/SaMD* startup.
*Software as a Medical Device: Software and medical device programs for medical purposes that assist in the diagnosis and treatment of diseases.

About the IP Merit Award
The Intellectual Property Merit Awards are presented annually by the JPO of the Ministry of Economy, Trade and Industry to individuals who have contributed to the development, dissemination, and awareness of the intellectual property rights system, and to companies that have made effective use of the system and contributed to its smooth operation and development. Both awards are collectively referred to as the "Intellectual Property Merit Awards.
Splink's Intellectual Property Initiatives
Splink develops and provides one-stop medical device programs in the field of brain healthcare, including dementia, with consistent solutions from prevention to diagnosis, under the vision of "Connecting all people, until the day they become connected.
As a deep-tech startup, how do we create and distribute our core technologies? We have positioned intellectual property as an important management resource, just like people, products, and money, and have formulated and promoted intellectual property strategies from this perspective since the founding of the company. In order to realize this vision, we are proactively creating a framework for IP creation, including internal awareness-raising, by establishing a dedicated IP management team, holding regular meetings between the business and R&D divisions to share information, disseminating in-house IP columns and providing training, and collaborating with a patent attorney firm that specializes in various fields. We are actively creating a framework for IP creation, including internal awareness-raising activities.
In 2021, we won the Grand Prix of the 3rd IP BASE AWARD sponsored by the Japan Patent Office, which recognizes the best IP players in domestic startups, and the following year, in 2022, we won the Grand Prix of the 2022 WIPO Global Awards sponsored by the World Intellectual Property Organization (WIPO), the intellectual property organization of the United Nations (UN). The following year, in 2022, the company won the Grand Prix at the 2022 WIPO Global Awards sponsored by the World Intellectual Property Organization (WIPO), the intellectual property organization of the United Nations (UN). Following the domestic and international awards, this is the first time in our history that we have won three IP-related awards.
Key Points of the Award
The following three points were made about the awarding of the IP Merit Award.
1. The company is working on AI-based solutions that lead to prevention and early diagnosis in the field of brain healthcare, including dementia, from R&D to social implementation in a comprehensive manner. Since its establishment, the representative director has positioned intellectual property as an important management asset as well as human, material, and financial resources, and has led the construction of a strategic intellectual property portfolio with an awareness of the speed at which intellectual property can be distributed. In addition to filing applications for core and improved technologies, the company also utilizes divisional applications to build a patent network.
2. Promote IP strategies that are integrated with management and business strategies, such as using IP information to identify potential competitors, obtain uniqueness and superiority, and consider countries of application in anticipation of global expansion. The IP division reports directly to the CEO and has access to information from all departments, including business management and R&D. A system that allows active intervention in the early stages of management and business strategies has become widespread. In addition, the IP department is also transferred to business divisions and concurrently works with information management in order to create synergy effects with other fields with expertise other than IP.
3. With three in-house designers, the brand design and trademark strategy are linked. In addition, the company licenses trademarks such as "Brain Health Care" at no cost, aiming to boost the resolution of medical issues that humanity will face in the future and to spread the concept of health care centered on brain health to society.
The key to the evaluation was the company's positioning of intellectual property as an important asset and its strategic use of it in its unique AI-based initiatives in the field of brain health care.
Comment from Mr. Hiroki Aoyama, Representative Director, Splink Corporation

We are very honored to receive the "Intellectual Property Merit Award. While the demand for accurate diagnosis of brain diseases is increasing, there is a serious shortage of doctors and specialists.
Last year saw the official approval of Japan's first drug to inhibit the progression of Alzheimer's disease, and there is no end to the number of innovations in drug discovery. Under such circumstances, the importance of accurate and early diagnosis in the field of brain diseases, which are difficult to diagnose, is increasing day by day. When considering the safe prescription of therapeutic drugs, it is important for companies like ours that develop diagnostic medical devices to promote their business while appropriately managing intellectual property to ensure a safe supply of products from the perspective of the Pharmaceutical Affairs Law and a stable supply of products/technology. Pharmaceutical affairs strategy and intellectual property strategy are inextricably linked, and research and development in a business-oriented manner is at the core of our business.
Splink will continue to integrate its intellectual property strategy and business strategy to further research and development and its implementation in society, and contribute to solving the issues of aging in the world with science and technology originating in Japan.
About Splink Corporation

With the vision of "Connecting all people, until the day we are all connected," we provide one-stop integrated solutions in the Brain Healthcare® area, including dementia, from early detection to diagnostic support.
Our main products are CQ test®, a unique cognitive function test that can easily measure cognitive function in healthy subjects; Brain Life Imaging®, an AI program that analyzes brain MRIs to measure and visualize the volume of the hippocampus, an area of the brain closely related to memory and learning, and provides an easy-to-understand report from the viewpoint of the examinee to promote awareness; and Braineer®, a brain image analysis program that quantifies and quantifies the degree of brain loss from brain MRIs to provide useful information for diagnosis and diagnostic support. Brain Life Imaging®" and "Braineer®," a brain image analysis program that provides useful diagnostic information by quantifying and quantifying the degree of brain loss from brain MRI, are our main products.
| name of company | Splink Corporation |
| Establishment | January 2017 |
| Location | 4F WAW Akasaka 35th Kowa Building, 1-14-14 Akasaka, Minato-ku, Tokyo |
| representative | Yuki Aoyama |
| Business Overview | Brain Health Care Business, Medical Device Program Business |
| uniform resouce locator | https://www.splinkns.com/ |









